Moleculin Biotech, Inc.
MBRXHealthcare|Biotechnology|US
$8.70
-0.03 (-0.34%)
DCF Value
$90.32
Tangible Book / Share
$1.55
Cash / Share
$25.57
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06788756 L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | Acute Myeloid Leukaemia (AML) | P2P3 | Recruiting | 312 | RCT, Double-blind | Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection. |
| NCT05879250 WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | P2 | Recruiting | 39 | Open-label | STAT3 Inhibitor WP1066 |
| NCT03388749 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | Leukemia, Myeloid, Acute | P1P2 | Completed | 20 | Open-label | Liposomal Annamycin |
| NCT03315039 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | Leukemia, Myeloid, Acute | P1P2 | Completed | 7 | Open-label | Liposomal Annamycin |
| NCT04887298 Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases | Sarcoma,Soft Tissue, Pulmonary Metastasis | P1P2 | Completed | 36 | Open-label | Liposomal Annamycin (L-Annamycin) |
| NCT05319587 Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | Leukemia, Myeloid, Acute | P1P2 | Completed | 22 | Open-label | Liposomal Annamycin, Cytarabine |
| NCT01826201 Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis | Psoriasis | P2 | Completed | 21 | Double-blind | MOL4239, Placebo |
| NCT05195723 Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers | Healthy Volunteer | P1 | Completed | 48 | RCT, Double-blind | WP1122, Placebo |
| NCT04702503 Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | P1 | Completed | 5 | Open-label | WP1220 |